Pharmaceutical-grade L-glutamine is not interchangeable with commodity or supplement-grade glutamine. Achieving the purity, stability, and consistency required for clinical use involves highly specialized purification processes, rigorous quality controls, and strict adherence to regulatory standards.
Only a small number of facilities worldwide are capable of producing L-glutamine at this level.
Niihara International’s decision to own and develop its own manufacturing capability is central to its mission. Ownership enables the company to:
Direct control over manufacturing allows for:
Many regions experience medication shortages due to reliance on long, fragile supply chains. Owning manufacturing reduces exposure to:
By eliminating layers of intermediaries, Niihara International can:
As awareness and adoption of L-glutamine therapy increase, scalable manufacturing ensures that supply can grow in parallel with need—without sacrificing quality.
Location: Ube, Yamaguchi Prefecture, Japan
Strategic Advantages:
This facility is intended to serve as a cornerstone of Niihara International’s long-term supply strategy, supporting sustainable access to therapy worldwide.
As Niihara International completes renovations on its facility in Ube, it will rely on Ajinomoto Inc. to supplement its manufacturing capabilities.
